PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25929975-1 2015 INTRODUCTION: The A2 allele of the CYP17 MspA1 polymorphism has been linked to higher levels of serum testosterone, progesterone, and estradiol. Testosterone 102-114 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 35-40 23628604-7 2013 The central role of PP2A in SET-mediated regulation of testosterone production was confirmed by the finding that SET promoted the lyase activity of P450c17 and that PP2A inhibited its lyase activity. Testosterone 55-67 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 148-155 25629114-0 2014 Re: the polymorphism (-600 C>A) of CpG methylation site at the promoter region of CYP17A1 and its association of male infertility and testosterone levels. Testosterone 137-149 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 85-92 24140493-0 2014 The polymorphism (-600 C>A) of CpG methylation site at the promoter region of CYP17A1 and its association of male infertility and testosterone levels. Testosterone 133-145 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 81-88 24223995-6 2013 The results of the present study demonstrated that CLA stimulates testosterone biosynthesis via CYP17A1, and endurance training led to the synthesis of testosterone in vivo by inducing the overexpression of CYP17A1 mRNA and protein in the Leydig cells of the testis. Testosterone 66-78 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 207-214 24223995-6 2013 The results of the present study demonstrated that CLA stimulates testosterone biosynthesis via CYP17A1, and endurance training led to the synthesis of testosterone in vivo by inducing the overexpression of CYP17A1 mRNA and protein in the Leydig cells of the testis. Testosterone 152-164 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 207-214 25208301-8 2015 CONCLUSIONS: The CYP17A1 gene -34T/C polymorphism might not be directly correlated with the PCOS, but might influence PCOS via the association of testosterone level and the HOMA-IR. Testosterone 146-158 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 17-24 25153259-4 2014 Testosterone-reduced expression of some steroidogenic enzymes/proteins (Tspo,StAR,Hsd3b1/2) and transcription factors (Nur77,Gata4,Dax1) was completely abrogated, while decreased expression of Star,Cyp11a1,Cyp17a1,Hsd17b4,Creb1a was partially prevented. Testosterone 0-12 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 206-213 23628604-8 2013 Taken together, these results reveal a specific, SET-initiated, PP2A-mediated, pathway that leads to the increased lyase activity of P450c17 and testosterone biosynthesis. Testosterone 145-157 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 133-140 23337755-3 2013 Abiraterone is a rationally designed potent inhibitor of cytochrome P450, family 17, subfamily A, polypeptide 1, which is essential for synthesis of testosterone from nongonadal precursors. Testosterone 149-161 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 57-111 22752297-1 2012 PURPOSE: Abiraterone is the active metabolite of the pro-drug abiraterone acetate (AA) and a selective inhibitor of CYP17, a key enzyme in testosterone synthesis, and improves overall survival in postdocetaxel metastatic castration-resistant prostate cancer (mCRPC). Testosterone 139-151 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 116-121 22451619-1 2012 Abiraterone acetate is an orally administered potent inhibitor of cytochrome P450, family 17, subfamily A, polypeptide 1 (CYP17), which is essential for synthesis of testosterone from cholesterol. Testosterone 166-178 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 66-120 22451619-1 2012 Abiraterone acetate is an orally administered potent inhibitor of cytochrome P450, family 17, subfamily A, polypeptide 1 (CYP17), which is essential for synthesis of testosterone from cholesterol. Testosterone 166-178 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 122-127 22123334-7 2012 Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase, a member of the cytochrome P450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis from the adrenal glands. Testosterone 195-207 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 47-76 22198164-2 2012 Abiraterone acetate (AA) is a rationally designed CYP17 inhibitor that blocks the conversion of androgens from non-gonadal precursors effectively, thus reducing testosterone to undetectable levels. Testosterone 161-173 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 50-55 17326004-3 2007 Sebocytes express very little of the key enzyme, cytochrome P450c17, necessary for synthesis of the androgenic prohormones dehydroepiandrosterone and androstenedione, however, these prohormones can be converted by sebocytes and sweat glands, and probably also by dermal papilla cells, into more potent androgens like testosterone and dihydrotestosterone. Testosterone 317-329 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 49-67 22184395-9 2012 Pretreatment CYP17 tumor expression >= 10% was correlated with increased bone marrow aspirate testosterone. Testosterone 97-109 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 13-18 22430753-3 2012 Abiraterone acetate was developed to specifically inhibit cytochrome P450 (CYP)17A1, which is an essential enzyme in the biosynthesis of testosterone. Testosterone 137-149 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 58-83 21676446-1 2011 OBJECTIVE: To investigate the association of CYP17 polymorphism with 17beta-estradiol (E2) and testosterone (T) concentration in hypospadias. Testosterone 95-107 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 45-50 22174412-1 2012 TOK-001 and abiraterone are potent 17-heteroarylsteroid (17-HAS) inhibitors of Cyp17, one of the rate-limiting enzymes in the biosynthesis of testosterone from cholesterol in prostate cancer cells. Testosterone 142-154 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 79-84 21985170-2 2011 Abiraterone acetate was developed to specifically inhibit cytochrome P450 (CYP)17A1, which is an essential enzyme in the biosynthesis of testosterone. Testosterone 137-149 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 58-83 21948762-5 2011 CYP17 TC and TT genotype testosterone and DHEA-SO(4) levels were lower in patients compared to controls. Testosterone 25-37 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 0-5 21511288-2 2011 As androgens have a significant role in the development of the male urethra, we sought to investigate the association between 2 functional polymorphisms, CYP17-A1/A2 and SRD5A2-V89L, which are involved in the biosynthesis of testosterone and dihydrotestosterone, respectively, in relation to hypospadias. Testosterone 225-237 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 154-162 14522586-8 2003 The brisk metabolism of 5alpha-pregnan-3alpha,17alpha-diol-20-one to androsterone by CYP17 explains how, when 5alpha-reductases are present, the testis can produce C(19) steroids androsterone and androstanediol from 17alpha-hydroxyprogesterone without the intermediacy of androstenedione and testosterone. Testosterone 292-304 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 85-90 15477877-3 2004 The linear trends across the CYP17 genotypes in serum-free testosterone and androstenedione levels were found, suggesting the importance of the polymorphism of CYP17 in determining the circulating androgen levels. Testosterone 59-71 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 29-34 15477877-3 2004 The linear trends across the CYP17 genotypes in serum-free testosterone and androstenedione levels were found, suggesting the importance of the polymorphism of CYP17 in determining the circulating androgen levels. Testosterone 59-71 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 160-165 16103457-2 2005 Four such genes, CYP17, CYP19, CYP11A1, and LH-beta, are involved in the synthesis and conversion of testosterone to dihydrotestosterone and estradiol. Testosterone 101-113 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 17-22 14560315-1 2004 Genes involved in the testosterone biosynthetic pathway - such as CYP17A1, CYP3A4, and SRD5A2 - represent strong candidates for affecting prostate cancer. Testosterone 22-34 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 66-73 12915666-2 2003 P450c17 can mediate testosterone biosynthesis via the conversion of pregnenolone to dehydroepiandrosterone (the delta(5) pathway) or via conversion of progesterone to androstenedione (the delta(4) pathway). Testosterone 20-32 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 0-7 11895872-2 2002 One such gene is CYP17, which encodes the cytochrome P450c17a enzyme responsible for the biosynthesis of testosterone. Testosterone 105-117 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 17-22 11895872-2 2002 One such gene is CYP17, which encodes the cytochrome P450c17a enzyme responsible for the biosynthesis of testosterone. Testosterone 105-117 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 42-60 11341336-0 2001 A common promotor variant in the cytochrome P450c17alpha (CYP17) gene is associated with bioavailability testosterone levels and bone size in men. Testosterone 105-117 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 33-56 11341336-0 2001 A common promotor variant in the cytochrome P450c17alpha (CYP17) gene is associated with bioavailability testosterone levels and bone size in men. Testosterone 105-117 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 58-63 34655046-3 2022 Studies have suggested that the increased testosterone synthesis seen in PCOS is driven in part by increased activity of CYP17A1, the rate-limiting enzyme for the formation of androgens in the gonads and adrenal cortex, which represents a critical factor driving enhanced testosterone secretion in PCOS. Testosterone 42-54 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 121-128 9858495-4 1999 Gonadal P450c17 expression was quantified by Western immunoblot analysis and related to testosterone secretion by cultured explants of fetal gonads. Testosterone 88-100 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 8-15 9858495-8 1999 P450c17 expression paralleled testosterone secretion, which decreased by Day 42, and was generally less in cultures of Meishan than of Yorkshire fetal gonads. Testosterone 30-42 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 0-7 11303586-5 2001 In particular, we wanted to test the hypotheses that the A2 allele in the CYP17 gene is associated with increased serum testosterone concentrations, and the L allele in the SRD5A2 gene is associated with reduced A-diol-g concentrations. Testosterone 120-132 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 74-79 9794458-2 1998 In gonadotropin-desensitized Leydig cells, from rats treated with high doses of human CG (hCG), testosterone production is markedly reduced, a finding that was attributed in part to reduction of CYP17 expression. Testosterone 96-108 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 195-200 9863627-9 1998 In contrast, the conversion of several precursors into testosterone remained stable or increased slightly during the first hours of r-hLH treatment and significantly increased at 24 h and this was associated with an increase of StAR, 3beta-HSD, P-450scc and P-450c17 mRNAs. Testosterone 55-67 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 258-266 34333840-3 2021 Abiraterone acetate blocks CYP17A1, which reduces testosterone synthesis from adrenal androgens or cholesterol in the testis, adrenal glands, and prostate cancer cells (2). Testosterone 50-62 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 27-34 34655046-3 2022 Studies have suggested that the increased testosterone synthesis seen in PCOS is driven in part by increased activity of CYP17A1, the rate-limiting enzyme for the formation of androgens in the gonads and adrenal cortex, which represents a critical factor driving enhanced testosterone secretion in PCOS. Testosterone 272-284 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 121-128 32712140-2 2020 This study aimed to reveal the significance of genetic polymorphisms in genes involved in androgen metabolism, including CYP17A1, AKR1C3, and HSD17B, on serum testosterone levels during ADT, as well as the prognosis of men undergoing ADT for metastatic prostate cancer (CaP). Testosterone 159-171 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 121-128 33436964-8 2021 Among the steroidogenic enzymes, CYP17A1 mediates steroid 17alpha-hydroxylation and 17,20-lyase reaction, necessary for testosterone production. Testosterone 120-132 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 33-40 29438723-3 2019 The compound is anticipated to efficiently dampen androgenic stimuli in the body by inhibiting CYP17A1, the prerequisite enzyme for the formation of dihydrotestosterone (DHT) and testosterone (T), and by blocking AR with high affinity and specificity. Testosterone 156-168 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 95-102 28179152-5 2017 Although the mechanisms of disruption were all different, they all resulted in decreased testosterone levels, some due to effects on CYP17, some earlier in the pathway. Testosterone 89-101 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 133-138 29438521-1 2018 STUDY QUESTION: Is the expression of steroidogenic enzyme 17alpha-Hydroxylase/17,20-Lyase (CYP17A1) down-regulated in Leydig cells (LCs) of men with spermatogenic failure and compensated impairment of LC function, i.e. a low testosterone to LH (T/LH) ratio? Testosterone 225-237 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 91-98 29438521-4 2018 CYP17A1 is a key enzyme in the testosterone pathway and has been implicated in the steroidogenic lesion produced by E2 stimulation. Testosterone 31-43 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 0-7 29951171-2 2018 It is a selective inhibitor of androgen biosynthesis which potentially and irreversibly blocks CYP17, a crucial enzyme in oestrogen and testosterone synthesis. Testosterone 136-148 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 95-100 28978327-3 2017 Especially upon treatment with the life-prolonging cytochrome P450 17-alpha-hydroxylase (Cyp17)-inhibitor, abiraterone, which has the ability to further suppress testosterone serum levels over LHRH therapy alone, continuation of LHRH therapy seems to be negligible. Testosterone 162-174 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 51-87 28978327-3 2017 Especially upon treatment with the life-prolonging cytochrome P450 17-alpha-hydroxylase (Cyp17)-inhibitor, abiraterone, which has the ability to further suppress testosterone serum levels over LHRH therapy alone, continuation of LHRH therapy seems to be negligible. Testosterone 162-174 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 89-94 26626779-6 2016 Nandrolone-induced testosterone increment was associated with upregulation of the steroidogenic acute regulatory protein (StAR) and downregulation of 17a-hydroxylase/17, 20 lyase (CYP17A1). Testosterone 19-31 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 180-187 26770559-7 2015 Men carrying the GG genotype for SNP rs1004467 (CYP17A1) had significantly elevated testosterone (P = 0.012) and dihydrotestosterone (DHT) levels (P = 0.024) as compared to carriers of the A allele. Testosterone 84-96 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 48-55 26770559-9 2015 Our findings suggest CYP17A1 rs1004467 SNP is associated with testosterone and DHT levels indicating the importance of this gene in influencing androgen levels in the circulatory system of PCa patients, hence could be used as a potential marker in PCa assessment. Testosterone 62-74 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 21-28 26150586-6 2015 Novel GnRH antagonists, such as degarelix, and cytochrome P450 17 (CYP17) enzyme inhibitors, such as ketoconazole, achieve castrate-equivalent serum testosterone levels much faster than traditional GnRH agonists without the need for coadministration of antiandrogens. Testosterone 149-161 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 47-65 26150586-6 2015 Novel GnRH antagonists, such as degarelix, and cytochrome P450 17 (CYP17) enzyme inhibitors, such as ketoconazole, achieve castrate-equivalent serum testosterone levels much faster than traditional GnRH agonists without the need for coadministration of antiandrogens. Testosterone 149-161 cytochrome P450 family 17 subfamily A member 1 Homo sapiens 67-72